CG Invites Co., Ltd. (KOSDAQ:083790)

Market Cap	71.51B -43.3%
Revenue (ttm)	30.11B +185.5%
Net Income	428.90M
EPS	5.58
Shares Out	76.89M
PE Ratio	166.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,079
Open	950.00
Previous Close	945.00
Day's Range	900.00 - 950.00
52-Week Range	711.00 - 1,667.00
Beta	0.06
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 71
• Stock Exchange: KOSDAQ
• Ticker Symbol: 083790

Financial Performance

In 2025, CG Invites's revenue was 27.39 billion, an increase of 277.64% compared to the previous year's 7.25 billion. Losses were -3.52 billion, -93.17% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error